HK1243408A1 - 制備5-[[4-[[嗎啉-2-基]甲基氨基]-5-(三氟甲基)-2-吡啶基]氨基]吡嗪-2-腈的方法 - Google Patents
制備5-[[4-[[嗎啉-2-基]甲基氨基]-5-(三氟甲基)-2-吡啶基]氨基]吡嗪-2-腈的方法Info
- Publication number
- HK1243408A1 HK1243408A1 HK18102805.1A HK18102805A HK1243408A1 HK 1243408 A1 HK1243408 A1 HK 1243408A1 HK 18102805 A HK18102805 A HK 18102805A HK 1243408 A1 HK1243408 A1 HK 1243408A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- carbonitrile
- morpholin
- pyrazine
- methylamino
- pyridyl
- Prior art date
Links
- YBYYWUUUGCNAHQ-UHFFFAOYSA-N 5-[[4-(morpholin-2-ylmethylamino)-5-(trifluoromethyl)pyridin-2-yl]amino]pyrazine-2-carbonitrile Chemical compound C1=C(NCC2OCCNC2)C(C(F)(F)F)=CN=C1NC1=CN=C(C#N)C=N1 YBYYWUUUGCNAHQ-UHFFFAOYSA-N 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261647200P | 2012-05-15 | 2012-05-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1243408A1 true HK1243408A1 (zh) | 2018-07-13 |
Family
ID=48468659
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15104108.4A HK1203529A1 (zh) | 2012-05-15 | 2015-04-28 | 嗎啉- -基 甲基氨基 三氟甲基 -吡啶基 氨基 吡嗪- -腈及其治療用途 |
HK18102805.1A HK1243408A1 (zh) | 2012-05-15 | 2018-02-27 | 制備5-[[4-[[嗎啉-2-基]甲基氨基]-5-(三氟甲基)-2-吡啶基]氨基]吡嗪-2-腈的方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15104108.4A HK1203529A1 (zh) | 2012-05-15 | 2015-04-28 | 嗎啉- -基 甲基氨基 三氟甲基 -吡啶基 氨基 吡嗪- -腈及其治療用途 |
Country Status (20)
Country | Link |
---|---|
US (3) | US9663503B2 (zh) |
EP (2) | EP3210980B1 (zh) |
JP (2) | JP6027230B2 (zh) |
KR (6) | KR102635954B1 (zh) |
CN (2) | CN106279142B (zh) |
AU (2) | AU2013261605B2 (zh) |
BR (1) | BR112014026801B1 (zh) |
CA (1) | CA2870837C (zh) |
DK (1) | DK2855448T3 (zh) |
ES (1) | ES2624307T3 (zh) |
HK (2) | HK1203529A1 (zh) |
IL (1) | IL235133A (zh) |
IN (1) | IN2014DN09221A (zh) |
MX (1) | MX358819B (zh) |
NZ (1) | NZ702050A (zh) |
PL (1) | PL2855448T3 (zh) |
RU (1) | RU2659786C2 (zh) |
SG (1) | SG11201407238VA (zh) |
WO (1) | WO2013171470A1 (zh) |
ZA (1) | ZA201408452B (zh) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2641693C2 (ru) | 2011-11-09 | 2018-01-22 | Кансер Ресёрч Текнолоджи Лимитед | Соединения 5-(пиридин-2-иламино)-пиразин-2-карбонитрила и их терапевтическое применение |
EP3210980B1 (en) | 2012-05-15 | 2024-04-03 | Cancer Research Technology Ltd | Process for manufacturing 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)- 2-pyridyl]amino]pyrazine-2-carbonitrile |
CN107501275B (zh) | 2012-12-07 | 2019-11-22 | 沃泰克斯药物股份有限公司 | 可用作atr激酶抑制剂的化合物 |
EP2970286A1 (en) | 2013-03-15 | 2016-01-20 | Vertex Pharmaceuticals Inc. | Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase |
RU2720408C2 (ru) | 2013-12-06 | 2020-04-29 | Вертекс Фармасьютикалз Инкорпорейтед | Способ получения ингибиторов atr киназы (варианты) |
AU2015271030B2 (en) | 2014-06-05 | 2019-05-16 | Vertex Pharmaceuticals Incorporated | Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo [1,5-a] pyrimidin-3-carboxamide compound useful as ATR kinase inhibitor, the preparation of said compound and different solid forms thereof |
ES2733847T3 (es) * | 2014-06-17 | 2019-12-03 | Vertex Pharma | Método para tratar cáncer usando una combinación de inhibidores de CHK1 y ATR |
WO2017059357A1 (en) | 2015-09-30 | 2017-04-06 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of dna damaging agents and atr inhibitors |
WO2018094325A1 (en) * | 2016-11-18 | 2018-05-24 | The Trustees Of Columbia University In The City Of New York | Therapeutic modulation of oncogenes by pharmacologic top2 targeting for cancer |
WO2018183891A1 (en) * | 2017-03-31 | 2018-10-04 | Cascadian Therapeutics | Combinations of chk1- and wee1 - inhibitors |
EP3609884A4 (en) * | 2017-04-10 | 2021-01-06 | Sierra Oncology, Inc. | CHK1 (SRA737) / PAPI COMBINATION METHOD FOR INHIBITION OF TUMOR GROWTH |
WO2018191299A1 (en) * | 2017-04-10 | 2018-10-18 | Sierra Oncology, Inc. | Chk1(sra737)wee1 inhibitor combination methods of inhibiting tumor growth |
EP3631444A4 (en) * | 2017-06-01 | 2021-06-09 | Sierra Oncology, Inc. | BIOMARKERS AND PATIENT SELECTION STRATEGIES |
CN107266897B (zh) * | 2017-08-04 | 2019-05-14 | 上海跃贝新材料科技股份有限公司 | 一种低粘度矿物增强pc/pet合金材料及其制备方法 |
CN112469391A (zh) * | 2018-02-26 | 2021-03-09 | 塞拉肿瘤学公司 | 包括chk1抑制剂的癌症的治疗方法 |
CN113631179A (zh) * | 2019-01-25 | 2021-11-09 | 努梅迪公司 | 用于治疗特发性肺纤维化的方法 |
US20220184091A1 (en) * | 2019-03-28 | 2022-06-16 | Sierra Oncology, Inc. | Methods of Treating Cancer with Chk1 Inhibitors |
CA3140123A1 (en) * | 2019-05-14 | 2020-11-19 | Sierra Oncology, Inc. | Methods of treating cancer using chk1 inhibitors |
CN110872277B (zh) * | 2019-11-14 | 2021-06-04 | 浙江大学 | N-取代芳环-2-氨基嘧啶类化合物及用途 |
CN110684083B (zh) * | 2019-12-06 | 2020-05-15 | 北京诺赛启研再生医学研究院有限公司 | 抑制黑色素合成的偶联物ii及其在药品和化妆品中的应用 |
CN110680928B (zh) * | 2019-12-06 | 2020-04-28 | 深圳前海港影生物科技有限公司 | 抑制黑色素合成的偶联物及其在药品和化妆品中的应用 |
TW202204348A (zh) * | 2020-04-07 | 2022-02-01 | 美商西爾拉癌症醫學公司 | Chk1抑制劑之合成方法 |
WO2023021328A1 (en) * | 2021-08-17 | 2023-02-23 | Bellus Health Cough Inc. | Preparation of a p2x3 antagonist |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773778A (en) | 1972-01-24 | 1973-11-20 | Squibb & Sons Inc | Sulfur derivatives of pyrazolo (3,4-b)pyridines |
IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
BR9609617B1 (pt) | 1995-07-06 | 2010-07-27 | derivados de 7h-pirrol[2,3-d]pirimidina, e composição farmacêutica. | |
ES2292812T3 (es) | 2001-10-19 | 2008-03-16 | Ortho-Mcneil Pharmaceutical, Inc. | 2-fenil benzimidazol e imidazo-(4,5)-piridinas como inhibidores de cds1/chk2 y coadyuvantes para quimioterapia o radioterapia en el tratamiento del cancer. |
WO2003035065A1 (en) | 2001-10-26 | 2003-05-01 | Aventis Pharmaceuticals Inc | Benzimidazoles and analogues and their use as protein kinases inhibitors |
WO2003037898A1 (en) | 2001-10-31 | 2003-05-08 | Bayer Healthcare Ag | Pyrimido [4,5-b] indole derivatives |
CA2484209C (en) | 2002-05-03 | 2013-06-11 | Exelixis, Inc. | Protein kinase modulators and methods of use |
US7202244B2 (en) * | 2002-05-29 | 2007-04-10 | Millennium Pharmaceuticals, Inc. | Chk-1 inhibitors |
MXPA06001098A (es) | 2003-07-29 | 2006-04-24 | Irm Llc | Compuestos y composiciones utiles como inhibidores de proteina cinasa. |
CN1863774B (zh) | 2003-10-08 | 2010-12-15 | Irm责任有限公司 | 用作蛋白激酶抑制剂的化合物和组合物 |
JP4845736B2 (ja) | 2003-10-14 | 2011-12-28 | アリゾナ ボード オブ リージェンツ オン ビハーフ ザ ユニバーシティー オブ アリゾナ | プロテインキナーゼ阻害剤 |
CA2542329A1 (en) | 2003-10-16 | 2005-04-28 | Chiron Corporation | 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of raf kinase for treatment of cancer |
US7163939B2 (en) | 2003-11-05 | 2007-01-16 | Abbott Laboratories | Macrocyclic kinase inhibitors |
US20050096324A1 (en) | 2003-11-05 | 2005-05-05 | Zhi-Fu Tao | Macrocyclic kinase inhibitors |
AU2005252160A1 (en) | 2004-04-13 | 2005-12-22 | Astellas Pharma Inc. | Polycyclic pyrazines as potassium ion channel modulators |
US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
AU2006239236A1 (en) | 2005-04-28 | 2006-11-02 | Supergen, Inc. | Protein kinase inhibitors |
WO2007000240A1 (en) | 2005-06-28 | 2007-01-04 | Sanofi-Aventis | Isoquinoline derivatives as inhibitors of rho-kinase |
TWI387592B (zh) | 2005-08-30 | 2013-03-01 | Novartis Ag | 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法 |
RU2008117298A (ru) | 2005-10-06 | 2009-11-20 | Шеринг Корпорейшн (US) | Пиразолопиримидины как ингибиторы протеинкиназ |
US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
GB0616747D0 (en) * | 2006-08-24 | 2006-10-04 | Astrazeneca Ab | Novel compounds |
CA2673920C (en) | 2006-12-27 | 2015-03-24 | Sanofi-Aventis | Cycloalkylamine substituted isoquinoline derivatives |
CN101679264A (zh) * | 2007-03-16 | 2010-03-24 | 斯克里普斯研究学院 | 粘着斑激酶抑制剂 |
WO2008117050A1 (en) | 2007-03-27 | 2008-10-02 | Astrazeneca Ab | Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer |
EP2170886A1 (en) | 2007-07-02 | 2010-04-07 | Cancer Research Technology Limited | 9h-pyrimido[4,5-b]indoles, 9h-pyrido[4',3':4,5]pyrrolo[2,3-d]pyridines, and 9h-1,3,6,9-tetraaza-fluorenes as chk1 kinase function inhibitors |
GB0719644D0 (en) | 2007-10-05 | 2007-11-14 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
GB0803018D0 (en) | 2008-02-19 | 2008-03-26 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
RU2641693C2 (ru) | 2011-11-09 | 2018-01-22 | Кансер Ресёрч Текнолоджи Лимитед | Соединения 5-(пиридин-2-иламино)-пиразин-2-карбонитрила и их терапевтическое применение |
EP3210980B1 (en) | 2012-05-15 | 2024-04-03 | Cancer Research Technology Ltd | Process for manufacturing 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)- 2-pyridyl]amino]pyrazine-2-carbonitrile |
-
2013
- 2013-05-14 EP EP17152400.2A patent/EP3210980B1/en active Active
- 2013-05-14 NZ NZ702050A patent/NZ702050A/en unknown
- 2013-05-14 SG SG11201407238VA patent/SG11201407238VA/en unknown
- 2013-05-14 IN IN9221DEN2014 patent/IN2014DN09221A/en unknown
- 2013-05-14 KR KR1020227037439A patent/KR102635954B1/ko active IP Right Grant
- 2013-05-14 DK DK13723910.9T patent/DK2855448T3/en active
- 2013-05-14 MX MX2014012881A patent/MX358819B/es active IP Right Grant
- 2013-05-14 BR BR112014026801-0A patent/BR112014026801B1/pt active IP Right Grant
- 2013-05-14 US US14/396,338 patent/US9663503B2/en active Active
- 2013-05-14 ES ES13723910.9T patent/ES2624307T3/es active Active
- 2013-05-14 JP JP2015512120A patent/JP6027230B2/ja active Active
- 2013-05-14 KR KR1020247004407A patent/KR20240023685A/ko active Application Filing
- 2013-05-14 KR KR1020207007411A patent/KR102246265B1/ko active IP Right Grant
- 2013-05-14 KR KR1020147031572A patent/KR102090792B1/ko active IP Right Grant
- 2013-05-14 CA CA2870837A patent/CA2870837C/en active Active
- 2013-05-14 RU RU2014147105A patent/RU2659786C2/ru active
- 2013-05-14 KR KR1020217012299A patent/KR102341637B1/ko active IP Right Grant
- 2013-05-14 EP EP13723910.9A patent/EP2855448B1/en active Active
- 2013-05-14 AU AU2013261605A patent/AU2013261605B2/en active Active
- 2013-05-14 KR KR1020217041302A patent/KR20210156333A/ko not_active Application Discontinuation
- 2013-05-14 CN CN201610652725.8A patent/CN106279142B/zh active Active
- 2013-05-14 CN CN201380025541.3A patent/CN104302635B/zh active Active
- 2013-05-14 WO PCT/GB2013/051233 patent/WO2013171470A1/en active Application Filing
- 2013-05-14 PL PL13723910T patent/PL2855448T3/pl unknown
-
2014
- 2014-10-19 IL IL235133A patent/IL235133A/en active IP Right Grant
- 2014-11-18 ZA ZA2014/08452A patent/ZA201408452B/en unknown
-
2015
- 2015-04-28 HK HK15104108.4A patent/HK1203529A1/zh unknown
-
2016
- 2016-10-13 JP JP2016201383A patent/JP6362652B2/ja active Active
-
2017
- 2017-05-04 US US15/587,270 patent/US10259806B2/en active Active
- 2017-11-28 AU AU2017268508A patent/AU2017268508C1/en active Active
-
2018
- 2018-02-27 HK HK18102805.1A patent/HK1243408A1/zh unknown
-
2020
- 2020-12-17 US US17/124,606 patent/US11787792B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1243408A1 (zh) | 制備5-[[4-[[嗎啉-2-基]甲基氨基]-5-(三氟甲基)-2-吡啶基]氨基]吡嗪-2-腈的方法 | |
IL231591A (en) | Preserved benzyl indazoles, a process for their preparation and use | |
EP2703530A4 (en) | CARBON FIBER MATERIAL, METHOD FOR PRODUCING THE CARBON FIBER MATERIAL AND MATERIAL WITH THE CARBON FIBER MATERIAL | |
EP2940024A4 (en) | BENZOXAZINE COMPOUND AND OXAZOLIDINONE, PREPARATION METHOD AND APPLICATION THEREOF | |
IL236135A0 (en) | Fluid compound for cleaning, method for cleaning a semiconductor component and method for its production | |
PL2912030T3 (pl) | Ulepszony sposób wytwarzania 5-(2,6-di-4-morfolinylo-4-pirymidynylo)-4- trifluorometylopirydyno-2-aminy | |
EP2822998A4 (en) | COMPATIBILIZED COMPOSITION, METHOD FOR FORMING THE SAME, AND ARTICLE COMPRISING SAME | |
EP2797587A4 (en) | VERY ROBUST CRUSHING TABLET AND METHOD OF MANUFACTURING THEM | |
PL2760811T3 (pl) | Sposób wytwarzania 2,3,3,3-tetrafluoropropenu | |
ZA201501764B (en) | Process for manufacturing benzoxazinones | |
EP2840073A4 (en) | SEMICONDUCTOR CERAMIC COMPOSITION, PROCESS FOR PRODUCING THE SAME, AND POSITIVE TEMPERATURE COEFFICIENT ELEMENT (PTC) | |
EP2881779A4 (en) | GLASS FOR GOGGLES AND METHODS OF DESIGNING AND MAKING SAME AND PROGRAM | |
EP3045550A4 (en) | Method for manufacturing press-molded article, and press-molded article | |
EP2762623A4 (en) | MULTI-PURPOSE FUNCTIONAL NONWOVEN FIBER, AND METHOD FOR MANUFACTURING THE SAME | |
EP2708640A4 (en) | MULTI-PURPOSE FUNCTIONAL COTTON AND METHOD FOR MANUFACTURING THE SAME | |
EP2781324A4 (en) | FORM AND METHOD FOR PRODUCING A MACHINE INTEGRATED FILTER THEREWITH | |
EP2703355A4 (en) | METHOD FOR MANUFACTURING LITHIUM TITANIUM OXIDES | |
IL232837A0 (en) | A process for the production of amino-benzoxazinones converted in position 4 | |
EP2978011A4 (en) | PROCESS FOR PREPARING A COMPLEX AND COMPOSITION | |
EP2762531B8 (en) | Material for manufacturing contact lens, method for manufacturing contact lens and contact lens manufactured therefrom | |
EP2836551A4 (en) | COMPATIBILIZED COMPOSITION, PROCESS FOR FORMATION THEREOF, AND ARTICLE COMPRISING SAME | |
GB201108825D0 (en) | Morpholino compounds, uses and methods | |
HK1211925A1 (zh) | 生產生物燃料的方法 | |
EP2749345A4 (en) | DEHUMIDIFICATION DEVICE AND METHOD OF MANUFACTURING THEREOF | |
SG10201602816XA (en) | B2f4 manufacturing process |